Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Clinical trial NCT02552121 · COMPLETED
Trial details
- NCT number
- NCT02552121
- Sponsor
- Seagen Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-30
- Primary completion
- 2017-12-13
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.